Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
• EnBW and SHS have concluded a 50MW power purchase agreement (PPA) from the planned EnBW offshore wind farm “He Drei…
The demand for sustainable product ideas has grown significantly, as this year's OE-A Competition clearly shows. The win…
The Supervisory Board of Fresenius Management SE extended Sara Hennicken's mandate as Chief Financial Officer (CFO) ahea…
Two and a half times the previous capacity Ecological design ensures low long-term operating costs Particularly importan…
. - Fresenius achieves the raised outlook for FY/23. Strong final quarter with continued good development of the Operati…
Martin Reder is taking over as CEO of the logistics service provider trans-o-flex, which specialises in the pharmaceutic…
MAIN5 GmbH & Co. KGaA, a leader in pharmaceutical consultancy, and ACCURIDS GmbH, a pioneer in enterprise data registrat…
The “OE-A Competition 2024” shows the many possibilities of flexible, organic, and printed electronics with inspiring pr…
. Albeck joins the Supervisory Board and will advise GEODIS CEO Marie-Christine Lombard on the Group's global strategi…